Pharmaceutical Executive: February 2026

View the Pharmaceutical Executive February 2026 issue in an interactive format.

Three key takeaways from the JPM industry reset offer clear clues to how biopharma companies—and leaders—must adapt to stand out and ultimately thrive in 2026.

From lessons in risk-taking—and building “from zero”—to career-defining pivots, Leonard Mazur, CEO of Citius Pharmaceuticals, reflects on 50-plus years in pharma.

Special Guest Op-Ed: What a decade of collaboration and shared effort reveals about the future of drug development.

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

The shifting landscape amid China's biotech rises presents both opportunities and geopolitical challenges for growth strategies.

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

How demand-driven development will help new products be more successful.

The AI dilemma facing biopharma—and what’s at risk.

As patient-centric evidence continues to shape the future of drug development, challenges around increased complexity and regulatory scrutiny must be addressed.